|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K2317/76 | (2013.01) |
| C07K 16/28 | (2006.01) | ||
| C07K 16/30 | (2006.01) | ||
| C07K2317/92 | (2013.01) | ||
| A61K 39/395 | (2006.01) | ||
| C07K2317/74 | (2013.01) | ||
| G01N 33/566 | (2013.01) | ||
| G01N 33/6854 | (2013.01) | ||
| A61K 45/06 | (2013.01) | ||
| C07K 16/30 | (2013.01) | ||
| C07K2317/24 | (2013.01) | ||
| C07K 16/2818 | (2013.01) | ||
| A61P 1/04 | (2018.01) | ||
| A61P 1/16 | (2018.01) | ||
| A61P 1/18 | (2018.01) | ||
| A61P 11/00 | (2018.01) | ||
| A61P 13/08 | (2018.01) | ||
| A61P 13/12 | (2018.01) | ||
| A61P 15/00 | (2018.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61K 39/3955 | (2013.01) | ||
| A61P 31/00 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 35/04 | (2018.01) | ||
| A61P 37/02 | (2018.01) | ||
| A61P 37/04 | (2018.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 5/14 | (2018.01) | ||
| A61P 7/00 | (2018.01) | ||
| Y02A 50/30 | (2018.01) |
| (11) | Patento numeris | 3514179 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 18211373.8 |
| Europos patento paraiškos padavimo data | 2015-01-23 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-07-24 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2022-11-02 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 201461931512 P | 2014-01-24 | US | |
| 201462059676 P | 2014-10-03 | US | |
| 201462094834 P | 2014-12-19 | US |
| (72) |
FREEMAN, Gordon, James , US
SHARPE, Arlene, Helen , US
BLATTLER, Walter, A. , US
MATARAZA, Jennifer, Marie , US
SABATOS-PEYTON, Catherine, Anne , US
CHANG, Hwai, Wen , US
FREY, Gerhard, Johann , US
|
| (73) |
Dana-Farber Cancer Institute, Inc. ,
450 Brookline Avenue, Boston, MA 02115-5450,
US
Novartis AG , Lichtstrasse 35, 4056 Basel, CH President and Fellows of Harvard College , 17 Quincy Street, Cambridge, MA 02138, US |
| (54) | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF |
| ANTIBODY MOLECULES TO PD-1 AND USES THEREOF |